Animal models of demyelination

Current Opinion in Neurology

Volumn 9, Issue 3, 1996, Pages 159-164

  Njenga, M Kariuki ^a   Rodriguez, Moses ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AUTOANTIBODY; CYTOKINE; IMMUNOGLOBULIN; MYELIN BASIC PROTEIN; SOMATOMEDIN C; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; CELL TRANSPLANTATION; CHEMOPROPHYLAXIS; DEMYELINATING DISEASE; GLIA CELL; INTRAVENOUS DRUG ADMINISTRATION; NONHUMAN; REVIEW; T LYMPHOCYTE;

EID: 0029948362     PISSN: 13507540     EISSN: None     Source Type: Journal    
DOI: 10.1097/00019052-199606000-00003     Document Type: Review

References (55)

1. Sun N, Perlman S: Spread of a neurotropic coronavirus to spinal cord • white matter via neurons and astrocytes. J Virol 1995, 69:633-641. This study addressed the mechanism of virus spread from the brain to the spinal cord, suggesting transneuronal migration followed by cell-to-cell spread within the spinal cord through glial cells.
2. Zurbriggen A, Grabber HU, Wagner A, Vandevelde M: Canine distemper virus persistence in the central nervous system is associated with non-cytolytic selective virus spread. J Virol 1995, 69:1678-1686.
3. Müller CF, Fatzer RS, Beck K, Vandevelde M, Zurbriggen A: Studies on canine distemper virus persistence in the central nervous system. Acta Neuropathol 1995, 89:438-445.
4. Sawicki SG, Lu J-H, Holmes KV: Persistent infection of cultured cells with mouse hepatitis virus (MHV) results from the epigenetic expression of the MHV receptor. J Virol 1995, 89:5535-5543.
5. Lipton HL, Twaddle G, Jelachich ML: The predominant virus antigen burden is present in macrophages in Theller's murine encephalomyelitis virus-induced demyelinating disease. J Virol 1995, 69:2525-2533.
6. Sun D, Le J, Yang S, Malostkey M, Coleclough C: Major role of antigen-presenting cells in the response of rat encephalitogenic T cells to myelin basic proteins. J Immunol 1993, 151:111-118.
7. Bell R, Lindsey J, Sobel R, Hodgkinson S, Steinman L: Diverse T cell receptor Vβ gene usage in the central nervous system In experimental allergic encephalomyelitis. J Immunol 1993, 150:4085-4092.
8. Musette P, Bureau J-F, Gachelin G, Kourilsky P, Brahic M: T lymphocyte • repertoire in Theiler's virus encephalomyelitis: the nonspecific infiltration of the central nervous system of infected SJL/J mice is associated with selective local T cell expansion. Eur J Immunol 1995, 25:1589-1593. Analysis of the TCR repertoire in the spinal cord of Theiler's virus-infected susceptible mice found all Vβ families, suggesting indiscriminate infiltration of T-cells in the CNS.
9. Rodriguez M, Nabozny GH, Thiemann RL, David CS: Influence of deletion of T cell receptor Vβ genes on the Theiler's virus model of multiple sclerosis. Autoimmunity 1994, 19:221-230.
10. Gold R, Giegerich G, Hartung HP, Toyka KV: T cell receptor (TCR) • usage in lewis rat experimental autoimmune encephalomyelitis: TCR βchain-variable-region Vβ8.2-positive T cells are essential for induction and course of disease. Proc Natl Acad Sci USA 1995, 92: 5850-5854. Previous studies suggested that TCR β-chain gene Vβ8.2 dominates in MBP-induced EAE. In this study, EAE was induced using T-cells depleted of the Vβ89.2-positive fraction, indicating that this particular T-cells population is not essential for induction of EAE.
11. Stohlman SA, Bergmann CC, van der Veen RC, Hinton DR: Mouse hepatitis virus-specific cytotoxic T lymphocytes protect from lethal Infection without eliminating virus from the central nervous system. J Virol 1995, 69:684-694.
12. Lin X, Thiemann R, Pease LR, Rodriguez M: VP1 and VP2 capsid proteins • of Theiler's virus are targets of H-2D-restricted cytotoxic lymphocytes in the central nervous system of B10 mice. Virology 1995, 214:91-99. The experiments demonstrated H-2D but not H-2K-restricted Theiler's virus capsid proteins-specific cytotoxic T-cells in the CNS of infected mice. The fact that susceptibility to TMEV-induced demyelination maps to the same D region of MHC suggests preferential antigen presentation by H-2D over H-2K in this picornaviral infection.
13. d transgene suppresses Theiler's virus-induced demyelination In susceptible strains of mice. J Neurovirology 1995, 1:111-117.
14. Massacesi L, Genain CP, Lee-Parritz D, Letvin NL, Canfield D, Hauser SL. • Active and passively Induced experimental autoimmune encephalomyelitis in common marmosets: a new model for multiple sclerosis. Ann Neurol 1995, 37:519-530. Reproducible EAE in primates should provide a useful model for analysis of immunopathologic mechanisms and therapeutic drugs.
15. Saoudi A, Simmonds S, Huitinga I, Mason D: Prevention of experimental allergic encephalomyelitis in rats by targeting autoantigen to B cells: evidence that the protective mechanism depends on changes in the cytokine response and migratory properties of the autoantigen-specific T cells. J Exp Med 1995, 182:335-344.
16. Khoury SJ, Gallon L, Chen W, Betres K, Russel ME, Hancock WW, •• Carpenter CB, Sayegh MF, Weiner HL: Mechanism of acquired thymic tolerance in experimental autoimmune encephalomyelitis: thymic dendritic-enriched cells induce specific peripheral T cell unresponsiveness in vivo. J Exp Med 1995, 182:357-366. This study investigated the mechanism of acquired thymic tolerance to MBP previously demonstrated to prevent induction of EAE. It suggests that the TCR of MBP-activated T-cells circulating through the thymus interact with thymic dendritic cells, leading to inactivation of these MBP-specific T-cells.
17. Javed NH, Gienapp IE, Cox KL, Whitacre CC: Exquisite peptlde specificity • of oral tolerance In experimental autoimmune encephalomyelitis. J Immunol 1995, 155:1599-1605. Lewis rats, treated orally with synthetic encephalitogenic MBP peptides GP 68-88 (from guinea pigs), but not with rat 68-88, were protected from EAE induced by both peptides. The two peptides differ by a single amino acid.
18. Samson MF, Smilek DE: Reversal of acute experimental autoimmune • encephalomyelitis and prevention of relapses by treatment with a myelin basic protein peptide analog modified to form long-lived peptide-MHC complexes. J Immunol 1995, 155:2737-2746. More effective treatment of EAE was realized with a substitute MBP peptide that complexed with MHC molecules for a prolonged period, an important consideration for future therapeutic strategies of MS.
19. Santambragio L, Crisi GM, Leu J, Hochwald GM, Ryan T, Thorbecke GJ: Tolerogenic forms of auto-antigens and cytokines in the induction of resistance to experimental allergic encephalomyelitis. J Neuroimmunol 1995, 58:211-222.
20. Tuohy VK, Thomas DM: Sequence 104-117 of myelin proteolipid protein is a cryptic encephalitogenic T cell determinant for SJL/J mice. J Neuroimmunol 1995, 56:161-170.
21. Abromson-Leeman S, Bronson R, Dorf ME: Experimental autoimmune • peripheral neuritis Induced in BALB/c mice by myelin basic protein-specific T cell clones. J Exp Med 1995, 182:587-592. As MS is exclusively a CNS disease, induction of peripheral nervous system demyelination by MBP-specific T-cells suggests that MBP is not the target antigen in MS.
22. Pender MP, Tabi Z, Nguyen KB, McCombe PA: The proximal peripheral nervous system is a major site of demyelination In experimental autoimmune encephalomyelitis Induced in the Lewis rat by a myelin basic protein-specific T cells clone. Acta Neuropathol 1995, 89:527-531.
23. Johns TG, de Rosbo NK, Menon KK, Abo S, Gonzales MF, Bernard CCA: Myelin oligodendrocyte glycoprotein induces a demyelinating encephalomyelitis resembling multiple sclerosis. J Immunol 1995, 154: 5536-5541.
24. Mendel I, de Rosbo NK, Ben-Nun A: A myelin peptide Induces typical • chronic experimental autoimmune encephalomyelitis in H-2b mice: fine specificity and T cell receptor Vβ expression of encephalitogenic T cells. Eur J Immunol 1995, 25:1951-1959. This study demonstrated induction of EAE by MOG peptide, pMOG 35-55, suggesting that MOG is a CNS autoantigen. This corroborated the finding of immune responses to MOG in patients with MS.
25. Johnson RS, Roder JC, Riordan JR: Over-expression of the DM-20 myelin proteolipid causes central nervous system demyelination In transgenic mice. J Neurochemistry 1995, 64:967-976.
26. Fiette L, Aubert C, Müller U, Huang S, Aguet M, Brahic M, Bureau J-F: •• Theiler's virus Infection of 129Sv mice that lack the Interferon α/β or Interferon y receptors. J Exp Med 1995, 181:2069-2076. This study indicates that IFN-α/β is crucial for resistance to acute CNS virus infection, whereas IFN-γ plays a role in chronic infection but is not required for demyelination. IFN-α/β receptor-deficient mice developed acute fatal encephalitis after TMEV infection; IFN-γ receptor-deficient mice developed a persistent infection and more severe demyelination than that seen in susceptible non-mutant mice.
27. Rodriguez M, Pavelko K, Coffman RL: Gamma Interferon Is critical for • resistance for Theiler's virus-induced demyelination. J Virol 1995, 69:7286-7290. These experiments demonstrated that treatment of mice with neutralizing antibodies to IFN-γ enhanced demyelination in susceptible mice and abrogated resistance in mice of resistant haplotype.
28. Issazadeh S, Mustafa M, Ljundahl Å, Höjeberg B, Dagerlind Å, Elde R, Olsson T: Interferon Y, interleukin 4 and transforming growth factor βin experimental autoimmune encephalomyelitis in Lewis rats: dynamics of cellular mRNA expression in the central nervous system and lymphoid cells. J Neurosci Res 1995, 40:579-590.
29. Karin N, Mitchell DJ, Brocke S, Ling N, Steinman L: Reversal of experimental autoimmune encephalomyelitis by a soluble peptide variant of a myelin basic protein epitope: T cell receptor antagonism and reduction of Interferon y and tumor necrosis factor a production. J Exp Med 1995, 180:2227-2237.
30. ••]) in therapy for demyelinating disease.
31. Brod SA, Khan M, Kerman RH, Pappolla M: Oral administration of human or murine Interferon alpha suppresses relapses and modifies adoptive transfer in experimental autoimmune encephalomyelitis. J Neuroimmunol 1995, 58:61-69.
32. Stohlman SA, Hinton DR, Cua D, Dimacali E, Sensintaffar J, Hofman FM, • Tahara SM, Yao Q: Tumor necrosis factor expression during mouse hepatitis virus-induced demyelinating encephalomyelitis. J Virol 1995, 69:5898-5903. This study shows that TNF has no effect on mouse hepatitis virus-induced demyelination.
33. Aranguez I, Torres C, Rubio N: The receptor for tumor necrosis factor on murine astrocytes: characterization, intracellular degradation, and regulation by cytokines and Theiler's murine encephalomyelitis virus. Glia 1995, 13:185-194.
34. Redford FJ, Hall SM, Smith KJ: Vascular changes and demyelination induced by the intraneural Injection of tumor necrosis factor. Brain 1995, 118:869-878.
35. Jenkins HG, Ikeda H: Tumor necrosis factor causes an increase In axonal transport of protein and demyelination in the mouse optic nerve. J Neurol Sci 1992, 108:99-104.
36. Selmaj K, Papierz W, Glabiñski A, Kohno T: Prevention of chronic relapsing experimental autoimmune encephalomyelitis by soluble tumor necrosis factor receptor I. J Neuroimmunol 1995, 56:135-141.
37. Johns LD, Flanders KC, Ranges GE, Sriram S: Successful treatment of experimental allergic encephalomyelitis with transforming growth factor-β1. J Immunol 1991, 147:1792-1796.
38. Karpus WJ, Pope JG, Peterson JD, Dal Canto MC, Miller SD: Inhibition of Theiler's virus-mediated demyelination by peripheral Immune tolerance induction. J Immunol 1995, 155:947-957.
39. Kappler JW, Roehm N, Marrack P: T cell tolerance by clonal elimination in the thymus. Cell 1987, 49:273-280.
40. Gaur A, Wiers B, Liu A, Rothbard J, Fathman C: Amelioration of autoimmune encephalomyelitis by myelin basic protein synthetic peptide-induced anergy. Science 1992, 258:1491-1494.
41. Gautman AM: Self and non-self peptides treat autoimmune encephalo• myelitis: T cell anergy or competition for major hlstocompatibility complex class II binding? Eur J Immunol 1995, 25:2059-2063. This study argues that peptide-induced tolerance is not a result of deletion or anergy of T-cells but the result of blocking MHC class II molecules.
42. Komoly S, Hudson LD, Webster HD, Bondy CA: Insulin-like growth factor 1 (IGF-1) gene expression is induced in astrocytes during experimental demyelination. Proc Natl Acad Sci USA 1992, 89:1894-1898.
43. Yao D-L, Liu X, Hudson LD, Webster HD: Insulin-like growth factor I treat•• ment reduces demyelination and up-regulates gene expression of myelin-related proteins in experimental autoimmune encephalitis. Proc Natl Acad Sci USA 1995, 92:6190-6194. The findings indicate that IGF-1 can reduce the number and areas of demyelinating lesions by enhancing myelin protein synthesis and oligodendrocyte proliferation. This may be of major significance in future therapeutic strategies for demyelinating diseases.
44. Franklin RJM, Bayley SA, Milner R, Ffrench-Constant C, Blakemore WF: •• Differentiation of O-2A progenitor cell line CG-4 into oligodendrocytes and astrocytes following transplantation into glia-deficient areas of CNS white matter. Glia 1995, 13:39-44. This study demonstrated remyelination after transplantation of a glial progenitor cell line. The cells differentiated into oligodendrocytes and astrocytes in vivo recreating the astrocyte-oligodendrocyte association which may be required for effective myelin production.
45. Blakemore WF, Crang AJ, Franklin RJM, Tang K, Ryder S: Glial cell transplants that are subsequently rejected can be used to influence regeneration of glial cell environments in the CNS. Glia 1995, 13:79-91.
46. Franklin RJM, Blakemore WF: Glial-cell transplantation and plasticity in the O-2A lineage-implications for CNS repair. Trends Neurosci 1995, 18:151-156.
47. Miller DJ, Sanbom KS, Katzmann JA, Rodriguez M: Monoclonal autoanti•• bodies promote central nervous system repair In an animal model of multiple sclerosis. J Neurosci 1994, 14:6230-6238. Two monoclonal autoantibodies, demonstrated subsequently to be natural autoantibodies [49], promoted CNS remyelination and reduced clinical deficits after virus-induced demyelination in mice. More recent investigation suggests that these autoantibodies act, at least in part, by suppressing CNS inflammation [50].
48. Miller DJ, Rodriguez M: Spontaneous and Induced remyelination in multiple sclerosis and the Theiler's virus model of central nervous system demyelination. Microscopy Res Tech 1995, 32:230-245.
49. Miller DJ, Rodnguez M: A monoclonal autoantlbody that promotes central nervous system remyelination in a model of multiple sclerosis Is a natural autoantibody encoded by germline immunoglobulin genes. J Immunol 1995, 154:2460-2469.
50. Miller DJ, Njenga MK, Murray PD, Leibowitz J, Rodriguez M: A monoclonal natural autoantibody that promotes remyelination suppresses central nervous system Inflammation and Increases virus expression after Theiler's virus-induced demyelination. Int Immunol 1996, 8:131-141.
51. Jung S, Toyka K, Hartung H-P: Suppression of experimental autoimmune encephalomyelitis in Lewis rats by antibodies against CD2. Eur J Immunol 1995, 25:1391-1398.
52. Kent SJ, Karlik SJ, Cannon C, Hines DK, Yednock TA, Fritz LC, Homer HC: A • monoclonal antibody to a4 integrin suppresses and reverses active experimental allergic encephalomyelitis. J Neuroimmunol 1995, 58:1-10. This study demonstrates that prevention of leukocyte trafficking into the CNS, by blocking expression of a leukocyte adhesion molecule, can suppress clinical and pathologic features of EAE.
53. Kobayashi Y, Kawai K, Honda H, Tomida S, Niimi N, Tamatani T, Miyasaka M, Yoshikai Y: Antibodies against leukocyte function-associated antigen-1 and against intracellular adhesion molecule-1 together suppress the progression of experimental allergic encephalomyelitis. Cellular Immunol 1995, 164:295-305.
54. Gijbels K, Galardy RE, Steinman L: Reversal of experimental autoimmune encephalomyelitis with a hydroxamate Inhibitor of matrix metalloproteases. J Clin Invest 1994, 94:2177-2182.
55. Racke MK, Bumett D, Pak S-H, Albert PS, Cannella B, Raine CS, McFarlin DE, Scott DE: Retinoid treatment of experimental allergic encephalomyelitis. IL-4 production correlates with Improved disease course. J Immunol 1995, 154:450-458.